Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 50 of 70 entries
View as:

Efficacy and Safety of Immunoglobulin Intravenous (Human) 10% (NewGam) in Primary Immune Thrombocytopenia

Phase: N/A Priority: Normal
NCT ID: NCT01349790 Org: User:
Start: 10/31/11 End: 07/31/13 Due: 07/31/14

Study to Investigate the Long-term Efficacy and Safety of Human-cl rhFVIII in Previously Treated Patients (PTPs)

Phase: N/A Priority: Normal
NCT ID: NCT01341912 Org: User:
Start: 06/30/11 End: 08/31/12 Due: 08/31/13

Study Comparing Weekly Intravenous Administration of OctaAlpha1 With a Marketed Preparation Glassia® in Subjects With Alpha-1-antitrypsin Deficiency

Phase: N/A Priority: Normal
NCT ID: NCT03385395 Org: User:
Start: 07/31/18 End: 12/31/19 Due: 12/31/20

Observational, Retrospective Study to Evaluate Coagulation Changes and the Influence of Antithrombin III Treatment in Patients With Severe COVID-19 Infection

Phase: N/A Priority: Normal
NCT ID: NCT04651400 Org: User:
Start: 10/19/20 End: 09/27/22 Due: 09/27/23

Study to Evaluate the Pharmacokinetics, Efficacy, Tolerability, and Safety of Subcutaneous Human Immunoglobulin (Newnorm) in Patients With Primary Immunodeficiency Diseases

Phase: N/A Priority: Normal
NCT ID: NCT04640142 Org: User:
Start: 08/04/21 End: 09/30/26 Due: 09/30/27

Trial Assessing Safety and Efficacy of Gammanorm® in Autoimmune Diseases

Phase: N/A Priority: Normal
NCT ID: NCT03656640 Org: User:
Start: 11/23/16 End: 12/09/19 Due: 12/09/20

Study to Investigate Immunogenicity, Efficacy and Safety of Treatment With Human-cl rhFVIII

Phase: N/A Priority: Normal
NCT ID: NCT01992549 Org: User:
Start: 04/30/14 End: 12/27/18 Due: 12/27/19

Study to Monitor Subcutaneous Human Immunoglobulin Administered at Modified Dosing Regimens in Patients With Primary Immunodeficiency Diseases

Phase: N/A Priority: Normal
NCT ID: NCT03939533 Org: User:
Start: 10/17/19 End: 01/03/22 Due: 01/03/23

CLINICAL PHASE III STUDY TO MONITOR THE SAFETY, TOLERABILITY AND EFFICACY OF SUBCUTANEOUS HUMAN IMMUNOGLOBULIN (OCTANORM) IN PATIENTS WITH PRIMARY IMMUNODEFICIENCY DISEASES, INCLUDING (BUT NOT LIMITED TO) THOSE WHO HAVE COMPLETED THE SCGAM-01 TRIAL

Phase: N/A Priority: Normal
NCT ID: NCT03907241 Org: User:
Start: 03/01/16 End: 09/05/19 Due: 09/05/20

Double-blind, Randomized, Placebo-controlled, Prospective Phase III Study Evaluating Efficacy and Safety of Panzyga in Primary Infection Prophylaxis in Patients With Chronic Lymphocytic Leukemia ("PRO-SID" Study)

Phase: N/A Priority: Normal
NCT ID: NCT04502030 Org: User:
Start: 10/05/20 End: 10/31/25 Due: 10/31/26

Study to Evaluate the Efficacy and Safety of PANZYGA in Pediatric Patients With Chronic Immune Thrombocytopenia (ITP)

Phase: N/A Priority: Normal
NCT ID: NCT03866798 Org: User:
Start: 01/21/20 End: 05/17/24 Due: 05/17/25

Clinical Study to Investigate the PK, Efficacy, and Safety of Wilate in Patients With Severe Hemophilia A

Phase: N/A Priority: Normal
NCT ID: NCT02954575 Org: User:
Start: 12/31/16 End: 03/29/18 Due: 03/29/19

Study of Octaplex, a Four-factor Prothrombin Complex Concentrate (4F-PCC) and Beriplex® P/N (Kcentra) for the Reversal of Vitamin K Antagonist (VKA) Induced Anticoagulation in Patients Needing Urgent Surgery With Significant Bleeding Risk.

Phase: N/A Priority: Normal
NCT ID: NCT02740335 Org: User:
Start: 06/08/17 End: 02/23/22 Due: 02/23/23

Gammanorm Quality of Life Study in Immunodeficient Patients Using Rapid Push or Pumps

Phase: N/A Priority: Normal
NCT ID: NCT02180763 Org: User:
Start: 04/30/14 End: 08/26/17 Due: 08/26/18

Assess the Efficacy and Safety of Personalized Prophylaxis Human-cl rhFVIII in Patients With Severe Haemophilia A

Phase: N/A Priority: Normal
NCT ID: NCT02256917 Org: User:
Start: 05/31/15 End: 09/30/18 Due: 09/30/19

Clinical Study to Investigate the Efficacy and Safety of Wilate During Prophylaxis in Previously Treated Patients With VWD

Phase: N/A Priority: Normal
NCT ID: NCT04052698 Org: User:
Start: 06/18/20 End: 04/23/22 Due: 04/23/23

Pharmacokinetic, Efficacy, and Safety Study of Octafibrin Compared to Haemocomplettan/Riastap

Phase: N/A Priority: Normal
NCT ID: NCT01575756 Org: User:
Start: 06/30/13 End: 01/31/15 Due: 01/31/16

Safety and Pharmacokinetics of Subcutaneous Injection of OCTA101 in Adult Patients With Severe Hemophilia A

Phase: N/A Priority: Normal
NCT ID: NCT04046848 Org: User:
Start: 07/03/19 End: 02/18/22 Due: 02/18/23

A Study to Compare Quality of Life and Satisfaction in Primary Immunodeficient Patients Treated With Subcutaneous Injections of Gammanorm® 165 mg/mL Administered With Two Different Delivery Devices: Injections Using Pump or Rapid Push

Phase: N/A Priority: Normal
NCT ID: NCT02503293 Org: User:
Start: 07/29/15 End: 12/11/17 Due: 12/11/18

Use of Fibryga, a Fibrinogen Concentrate in Real World: Retrospective Collection of Clinical Data

Phase: N/A Priority: Normal
NCT ID: NCT04106895 Org: User:
Start: 02/21/19 End: 02/10/20 Due: 02/10/21

Surveillance of Safety and Efficacy of Wilate in Patients With Von Willebrand Disease

Phase: N/A Priority: Normal
NCT ID: NCT01602419 Org: User:
Start: 10/31/12 End: 04/30/18 Due: 04/30/19

Study to Evaluate the Efficacy, Tolerability and Safety of Octanorm in Patients With Primary Immunodeficiency Diseases

Phase: N/A Priority: Normal
NCT ID: NCT03988426 Org: User:
Start: 03/07/17 End: 01/26/18 Due: 01/26/19

Active-control Randomised Trial Comparing 4-factor Prothrombin Complex Concentrate With Frozen Plasma in Cardiac Surgery

Phase: N/A Priority: Normal
NCT ID: NCT05523297 Org: User:
Start: 11/30/22 End: 06/28/24 Due: 06/28/25

Phase III Study To Compare The Effect of Panzyga Versus Placebo in Patients With Pediatric Acute-onset Neuropsychiatric Syndrome (PANS/PANDAS)

Phase: N/A Priority: Normal
NCT ID: NCT04508530 Org: User:
Start: 06/30/21 End: 10/30/24 Due: 10/30/25

Study Evaluating Efficacy and Safety of Octagam 10% in Patients With Dermatomyositis (Idiopathic Inflammatory Myopathy)

Phase: N/A Priority: Normal
NCT ID: NCT02728752 Org: User:
Start: 02/27/17 End: 11/05/19 Due: 11/05/20